Seres Therapeutics (MCRB) Total Debt (2019 - 2024)
Historic Total Debt for Seres Therapeutics (MCRB) over the last 7 years, with Q2 2024 value amounting to $102.5 million.
- Seres Therapeutics' Total Debt rose 173.91% to $102.5 million in Q2 2024 from the same period last year, while for Jun 2024 it was $102.5 million, marking a year-over-year increase of 173.91%. This contributed to the annual value of $101.5 million for FY2023, which is 10071.55% up from last year.
- Latest data reveals that Seres Therapeutics reported Total Debt of $102.5 million as of Q2 2024, which was up 173.91% from $102.0 million recorded in Q1 2024.
- Seres Therapeutics' 5-year Total Debt high stood at $102.5 million for Q2 2024, and its period low was $16.1 million during Q3 2021.
- For the 5-year period, Seres Therapeutics' Total Debt averaged around $52.4 million, with its median value being $50.5 million (2022).
- Its Total Debt has fluctuated over the past 5 years, first plummeted by 3547.26% in 2021, then surged by 21554.88% in 2022.
- Over the past 5 years, Seres Therapeutics' Total Debt (Quarter) stood at $24.6 million in 2020, then increased by 0.02% to $24.6 million in 2021, then surged by 105.3% to $50.6 million in 2022, then skyrocketed by 100.72% to $101.5 million in 2023, then increased by 0.94% to $102.5 million in 2024.
- Its last three reported values are $102.5 million in Q2 2024, $102.0 million for Q1 2024, and $101.5 million during Q4 2023.